The #1 Nanomedicine Knowledge Platform
By distilling complex research, industry trends, and regulatory, clinical, and preclinical data (LNPs, RNA, delivery tech, ADCs & personalized medicine) into clear, actionable insights, NanoSphere accelerates nanomedicine from bench to bedside—fueling scientists, regulators, startups, and investors to act, build, and scale.
Follow us
Our audience is facing three main problems:
- Lack of Visibility
Innovative research and emerging voices often go unnoticed—especially outside top-tier journals or major institutions.
- Fragmented Communication
Limited collaboration between academia, industry, clinicians and regulators slows translation and real-world application.
- Overwhelming Complexity
Regulatory jargon, clinical trial data, and scientific literature are hard to navigate, especially without access to a live, structured nanomedicine market database.
We decode LNPs, RNA, delivery tech, ADCs & personalized medicine through:
Monthly Newsletter
A monthly digest translating nanomedicine research, regulation, industry/business and clinical updates into clear, actionable insights.
For whom: Academia, industry, and regulators.
How it helps:
- Breaks silos by connecting sectors
- Translates jargon into accessible language
- Accelerates lab-to-market translation
- Sparks collaboration through shared knowledge.
Curated by our team of experts.
Monthly Articles
A deep-dive into key nanomedicine topics—backed by real-time tools like our approved drug database and clinical pipeline tracker.
For whom: Experts and decision-makers in biotech, and regulation.
How it helps:
- Bridges sectors through shared, cross-functional knowledge
- Gives visibility to global innovators with practical, forward-looking content
- Enables action with live tools: approved drug database, modality trackers, and trial overviews.
Written by NanoSphere, reviewed by our collaborators.
Weekly Interview Feature
A monthly feature highlighting diverse nanomedicine innovators—from rising researchers to industry leaders—sharing their vision, challenges, and next steps.
Check here for more.
For whom: Academia, industry, and regulatory professionals seeking inspiration and direction.
How it helps:
- Amplifies voices often overlooked by top journals and platforms
- Reveals real-world perspectives on the future of nanomedicine
- Connects sectors through shared foresight and experience
- Sparks collaboration by surfacing next-gen ideas and needs.
Check here for more.
Daily Academic Digests
A daily series spotlighting global academic papers, enhanced with NanoSphere advice on clinical translation.
For whom: Innovators across academia, biotech, and regulatory fields.
How it helps:
- Elevates research beyond top journals
- Translates scientific jargon into practical value
- Connects sectors through expert context
- Boosts visibility and cross-sector engagement
Curated by our experts for a clinical translation.
Nanomedicine guide GPT
This GPT is a nanomedicine and nanotechnology assistant powered by a specialized database, designed to help you with lipid nanoparticles (LNPs), polymer-based drug delivery systems, and nucleic acids such as mRNA, DNA, and RNA therapeutics.
N/P ratio calculator GPT
This prompt is backed by scientific references to assist you in calculating N/P ratios, molecular weights, and the required mass of the substance for your formulation.
subscribe to our newsletter by clicking on the video
Join 2,800+ experts receiving clear, curated insights bridging research, regulation, and real-world application—delivered monthly.
NanoSphere doesn’t just report nanomedicine developments—it translates them.
What does each get out of NanoSphere?
What does each get out of NanoSphere?
Academics → Visibility + industry context
Biotech teams → Tech scouting + BD leads
Regulators → Clinical relevance & safety lenses
Investors → Emerging trends + platform potential
Just make sure to follow us here.
Followers
NanoSphere has reached 2,800 LinkedIn followers—a 260% increase since July 2024.
Monthly Website Visits
Monthly visits to site have grown by around 338% since our newsletter in October 2024.
Global hub
From Boston to Basel, NanoSphere is driving the nanomedicine conversation in 40+ global centers.
Make Nanomedicine Clear, Connected, and Clinical
Every article, interview, and tool helps nanomedicine translate faster, smarter, and more collaboratively.
Every article, interview, and tool helps nanomedicine translate faster, smarter, and more collaboratively.
NanoSphere envisions to own the global conversation around nanomedicine.
What sets us apart?
Words from our stakeholders
„Thank you to the NanoSphere team for the thoughtful interview and for providing the field with a hub of conversation that is difficult to find outside of conferences. A clear labor of love!”
About
Sean Bedingfield PhD, Senior Advisor at Eli Lilly and Company's Genetic Medicine division
Sean Bedingfield PhD, Senior Advisor at Eli Lilly and Company's Genetic Medicine division
- NanoSphere interview
A Clearer, Faster Future for Nanomedicine
NanoSphere envisions a world where life-changing nanomedicine innovations are no longer buried in silos or slowed by complexity. By translating knowledge into impact, NanoSphere accelerates the journey from bench to bedside—so that scientific breakthroughs reach patients faster, smarter, and with greater global reach.
We are building a future where:
Researchers gain visibility beyond academic journals.
Industry, regulators, and academia collaborate seamlessly.
Every insight is accessible, actionable, and aligned with real-world needs.
subscribe to our newsletter by clicking on the video
Join 2,800+ experts receiving clear, curated insights bridging research, regulation, and real-world application—delivered monthly.